Cite as: 592 U. S. ____ (2021)               1

                     ROBERTS, C. J., concurring

SUPREME COURT OF THE UNITED STATES
                           _________________

                            No. 20A34
                           _________________


    FOOD AND DRUG ADMINISTRATION, ET AL. v.
     AMERICAN COLLEGE OF OBSTETRICIANS
          AND GYNECOLOGISTS, ET AL.
                  ON APPLICATION FOR STAY
                        [January 12, 2021]

   The application for stay presented to THE CHIEF JUSTICE
and by him referred to the Court is granted, and the district
court’s July 13, 2020 order granting a preliminary injunc-
tion is stayed pending disposition of the appeal in the
United States Court of Appeals for the Fourth Circuit and
disposition of the petition for a writ of certiorari, if such writ
is timely sought. Should the petition for a writ of certiorari
be denied, this stay shall terminate automatically. In the
event the petition for a writ of certiorari is granted, the stay
shall terminate upon the sending down of the judgment of
this Court.
   JUSTICE BREYER would deny the application.
   CHIEF JUSTICE ROBERTS, concurring in the grant of ap-
plication for stay.
   The question before us is not whether the requirements
for dispensing mifepristone impose an undue burden on a
woman’s right to an abortion as a general matter. The
question is instead whether the District Court properly or-
dered the Food and Drug Administration to lift those estab-
lished requirements because of the court’s own evaluation
of the impact of the COVID–19 pandemic. Here as in re-
lated contexts concerning government responses to the pan-
demic, my view is that courts owe significant deference to
the politically accountable entities with the “background,
2    FDA v. AMERICAN COLLEGE OF OBSTETRICIANS AND
                    GYNECOLOGISTS
                  ROBERTS, C. J., concurring

competence, and expertise to assess public health.” South
Bay United Pentecostal Church v. Newsom, 590 U. S. ___,
___ (2020) (ROBERTS, C. J., concurring in denial of applica-
tion for injunctive relief) (slip op., at 2). In light of those
considerations, I do not see a sufficient basis here for the
District Court to compel the FDA to alter the regimen for
medical abortion.
                    Cite as: 592 U. S. ____ (2021)                 1

                      SOTOMAYOR, J., dissenting

SUPREME COURT OF THE UNITED STATES
                            _________________

                             No. 20A34
                            _________________


     FOOD AND DRUG ADMINISTRATION, ET AL. v.
      AMERICAN COLLEGE OF OBSTETRICIANS
           AND GYNECOLOGISTS, ET AL.
                   ON APPLICATION FOR STAY
                         [January 12, 2021]

   JUSTICE SOTOMAYOR, with whom JUSTICE KAGAN joins,
dissenting from grant of application for stay.
   The majority of American women seeking abortion care
during the first 10 weeks of pregnancy rely on medication
abortion. Medication abortion involves taking two prescrip-
tion drugs, mifepristone and misoprostol, which together
induce the equivalent of an early miscarriage. The Food
and Drug Administration (FDA) allows patients to receive
all physician consultations for a medication abortion virtu-
ally and to take both prescriptions at home without medical
supervision. To obtain mifepristone, however, the FDA re-
quires patients to go to a hospital, clinic, or medical office
to pick up the drug in person and sign a disclosure form. 1
Of the over 20,000 FDA-approved drugs, mifepristone is the
only one that the FDA requires to be picked up in person
for patients to take at home.
   The FDA’s unique treatment of mifepristone has become
even more pronounced during the COVID–19 pandemic.
After the Secretary of Health and Human Services (HHS)
declared the COVID–19 pandemic a public health emer-
gency, the FDA and HHS waived in-person requirements


——————
  1 Misoprostol, meanwhile, can be obtained through a retail or mail-

order pharmacy.
2    FDA v. AMERICAN COLLEGE OF OBSTETRICIANS AND
                    GYNECOLOGISTS
                  SOTOMAYOR, J., dissenting

for several other drugs, including certain controlled sub-
stances, but not for mifepristone. As a result, Government
policy now permits patients to receive prescriptions for
powerful opioids without leaving home, yet still requires
women to travel to a doctor’s office to pick up mifepristone,
only to turn around, go home, and ingest it without super-
vision.
   In July, a District Court enjoined the FDA’s in-person dis-
pensing and signature requirements for mifepristone for
the duration of the COVID–19 pandemic. Today, the Court
grants extraordinary relief to reinstate them. Because the
FDA’s policy imposes an unnecessary, unjustifiable, irra-
tional, and undue burden on women seeking an abortion
during the current pandemic, and because the Government
has not demonstrated irreparable harm from the injunc-
tion, I dissent.
                              I
                             A
  As of early January, the United States has endured over
20 million reported COVID–19 cases and over 350,000
deaths from the disease. 2 COVID–19 spreads easily from
person to person and many individuals infected by COVID–
19 display no symptoms. The Centers for Disease Control
and Prevention (CDC) have therefore advised people to
avoid close contact with others, especially in indoor spaces,
to the greatest extent possible. 3 The COVID–19 pandemic
has thus made many typical activities more difficult and
dangerous. A trip to the doctor’s office is no exception.
  As a result, the Federal Government has urged

——————
  2 See CDC, United States COVID–19 Cases and Deaths by State (up-

dated Jan. 6, 2021), https://covid.cdc.gov/covid-data-tracker/#cases_
casesper100k.
  3 See CDC, Things To Know About the COVID–19 Pandemic (updated

Dec.    31,   2020),  https://www.cdc.gov/coronavirus/2019-ncov/your-
health/need-to-know.html.
                      Cite as: 592 U. S. ____ (2021)                      3

                        SOTOMAYOR, J., dissenting

healthcare providers and patients to take advantage of tel-
emedicine. For example, the CDC has advised medical pro-
viders to use telemedicine “whenever possible” because it is
“the best way to protect patients and staff from COVID–
19.” 4 The CDC has likewise informed patients that they
should use telemedicine “[t]o reduce the risk of COVID–19
and keep you and your family healthy.” 5 As mentioned
above, the FDA and HHS have waived many in-person drug
distribution requirements because they could “put patients
and others at risk for transmission of the coronavirus.” 6
For instance, the FDA no longer requires patients to
undergo in-person procedures, such as laboratory tests or
MRIs, before being prescribed certain drugs. Similarly,
HHS now permits physicians to use telemedicine, rather
than in-person evaluations, before prescribing certain con-
trolled substances, including opioids.
   The Government has thus recognized that in-person
healthcare during the COVID–19 pandemic poses a signifi-
cant risk to patients’ health, and it has acted to help pa-
tients “ ‘ access healthcare they need from their home, with-
out worrying about putting themselves or others at risk
during the COVID–19 outbreak.’ ” 7 Yet the Government
has refused to extend that same grace to women seeking

——————
  4 See CDC, Prepare Your Practice for COVID–19 (updated June 12,

2020),     https://www.cdc.gov/coronavirus/2019-ncov/hcp/preparedness-
resources.html.
  5 See CDC, Telemedicine: What Does It Mean and Why Should You

Care? (updated Sept. 15, 2020), https://www.cdc.gov/coronavirus/2019-
ncov/downloads/global-covid-19/Telemedicine-Factsheet-MIT.pdf.
  6 FDA,    Policy for Certain REMS Requirements During the
COVID–19 Public Health Emergency: Guidance for Industry and Health
Care Professionals 7 (Mar. 2020), https://www.fda.gov/media/136317/
download.
  7 Dept. of Health & Human Servs., Secretary Azar Announces Historic

Expansion of Telehealth Access To Combat COVID–19 (Mar. 17, 2020),
https://www.hhs.gov/about/news/2020/03/17/secretary -azar- an-
nounces -historic -expansion-of-telehealth-access -to- combat-covid-19.html.
4   FDA v. AMERICAN COLLEGE OF OBSTETRICIANS AND
                   GYNECOLOGISTS
                 SOTOMAYOR, J., dissenting

medication abortions. Women must still go to a clinic in
person to pick up their mifepristone prescriptions, even
though physicians may provide all counseling virtually,
women may ingest the drug unsupervised at home, and any
complications will occur long after the patient has left the
clinic.
                               B
   This summer, representatives of the Nation’s healthcare
providers, including the American College of Obstetricians
and Gynecologists (ACOG) and the Council of University
Chairs of Obstetrics and Gynecology (CUCOG), along with
SisterSong Women of Color Reproductive Justice Collec-
tive, filed suit to enjoin the Federal Government from en-
forcing mifepristone’s in-person requirements during the
COVID–19 pandemic. In a thorough opinion, the District
Court concluded that the in-person requirements likely
placed a “substantial obstacle” in the path of women seek-
ing abortions during the pandemic. 

,
216 (D Md. 2020) (internal quotation marks omitted). The
court preliminarily enjoined the Government from enforc-
ing mifepristone’s in-person requirements during the pan-
demic.

The Court of Appeals for the Fourth
Circuit denied the Government’s request for a stay of that
injunction. The Government then applied for a stay from
this Court.
   In early October, this Court issued an order holding the
Government’s application in abeyance so the District Court
could consider a yet-to-be-filed motion from the Govern-
ment to dissolve, stay, or modify the injunction, “including
on the ground that relevant circumstances have changed.”
592 U. S. ___ (2020) (slip op., at 1). The Government filed
such a motion, but the District Court concluded that no
changed circumstances justified a stay or dissolution of the
injunction. ___ F. Supp. 3d ___, ___, 

, *14
(D Md., Dec. 9, 2020). Indeed, the District Court found that
                   Cite as: 592 U. S. ____ (2021)               5

                     SOTOMAYOR, J., dissenting

the pandemic had gotten only worse since the summer.

The number of COVID–19 cases in the United States
had increased four-fold, the number of deaths had more
than doubled, and the pandemic was expected to intensify
in the coming winter months.

therefore denied the motion.
   The Government has now returned to this Court, asking
again for a stay of the District Court’s injunction. Although
the COVID–19 pandemic has only worsened since October,
the Court now grants the Government’s request.
   A stay of a district court’s injunction is “ ‘ extraordinary’ ”
relief. See Williams v. Zbaraz, 

, 1311 (1979)
(Stevens, J., in chambers). “An applicant for a stay must
meet a heavy burden of showing not only that the judgment
of the lower court was erroneous on the merits, but also that
the applicant will suffer irreparable injury if the judgment
is not stayed pending his appeal.” Ruckelshaus v. Monsanto
Co., 

, 1316 (1983) (Blackmun, J., in cham-
bers) (internal quotation marks omitted); see also Mary-
land v. King, 

, 1302 (2012) (ROBERTS, C. J.,
in chambers). The District Court was correct to conclude
that the FDA’s unique regulation of mifepristone during the
COVID–19 pandemic “plac[es] a substantial obstacle in the
path of a woman seeking an abortion.” Planned Parenthood
of Southeastern Pa. v. Casey, 

, 877 (1992) (plu-
rality opinion); see also June Medical Services L. L. C. v.
Russo, 591 U. S. ___, ___ (2020) (plurality opinion) (slip op.,
at 1) (“ ‘ “[H]ealth regulations that have the purpose or effect
of presenting a substantial obstacle to a woman seeking an
abortion” ’ . . . are . . . ‘constitutionally invalid’ ” (quoting
Whole Woman’s Health v. Hellerstedt, 579 U. S. ___, ___
(2016) (slip op., at 1)); June Medical, 591 U. S., at ___
(ROBERTS, C. J., concurring in judgment) (slip op., at 11)
(“In this case, Casey’s requirement of finding a substantial
obstacle before invalidating an abortion regulation is . . . a
6     FDA v. AMERICAN COLLEGE OF OBSTETRICIANS AND
                     GYNECOLOGISTS
                   SOTOMAYOR, J., dissenting

sufficient basis for the decision”);

___ (ALITO, J., dis-
senting) (slip op., at 3) (“Under our precedent, the critical
question . . . is whether [a] challenged . . . law places a ‘sub-
stantial obstacle in the path of a woman seeking an abor-
tion of a nonviable fetus’ ” (quoting 

(plurality opinion))). The Government has moreover failed
to demonstrate irreparable harm. For these reasons, I
would deny the Government’s request.
                               II
                               A
   Due to particularly severe health risks, vastly limited
clinic options, and the 10-week window for obtaining a med-
ication abortion, the FDA’s requirement that women obtain
mifepristone in person during the COVID–19 pandemic
places an unnecessary and undue burden on their right to
abortion. Pregnancy itself puts a woman at increased risk
for severe consequences from COVID–19. In addition, more
than half of women who have abortions are women of color,
and COVID–19’s mortality rate is three times higher for
Black and Hispanic individuals than non-Hispanic White
individuals. On top of that, three-quarters of abortion pa-
tients have low incomes, making them more likely to rely
on public transportation to get to a clinic to pick up their
medication. Such patients must bear further risk of expo-
sure while they travel, sometimes for several hours each
way, to clinics often located far from their homes. 8 Finally,
——————
   8 For instance, according to the most recently available data, Arkansas

has just three abortion clinics, and 77% of women of childbearing age live
in a county without any clinic. Mississippi has just one abortion clinic,
and 91% of women of childbearing age live in a county without any clinic.
Missouri has just three abortion clinics, and 78% of women of childbear-
ing age live in a county without a clinic. North Dakota has just one abor-
tion clinic, and 72% of women of childbearing age live in a county without
any clinic. See Guttmacher Institute, R. Jones, E. Witwer, & J. Jerman,
Abortion Incidence and Service Availability in the United States, 2017,
pp. 17–18 (2019).
                     Cite as: 592 U. S. ____ (2021)                     7

                       SOTOMAYOR, J., dissenting

minority and low-income populations are more likely to live
in intergenerational housing, so patients risk infecting not
just themselves, but also elderly parents and grandparents.
These risks alone are significant deterrents for women
seeking a medication abortion that requires in-person
pickup.
   The obstacles are even greater, however, because medical
offices have dramatically reduced availability during the
pandemic. The District Court received unrebutted evidence
that some healthcare facilities that normally provide medi-
cation abortion services have closed at various times during
the pandemic, making it impossible for women to pick up
their mifepristone. Even those practices that remain open
may operate at decreased capacity to maintain social dis-
tancing, sometimes seeing just 10% to 25% of their typical
patient load. One doctor described how the pandemic
caused her hospital system to stop in-person visits to all but
three primary care clinics. Abortion patients were referred
to distantly located family planning clinics that were open
only a half day per week. 9
   The District Court found that these obstacles can cause
women to miss the 10-week window for a medication abor-
tion altogether. The average American woman does not dis-
cover that she is pregnant until 5.5 weeks, and nearly a
quarter of women do not discover their pregnancies until 7

——————
   9 Data has begun to bear out the difficulties women have faced in ac-

cessing reproductive care. In a June 2020 survey, one in three women
reported that they had delayed or canceled a visit for sexual or reproduc-
tive care or had trouble accessing birth control during the pandemic. See
L. Lindberg, A. VandeVusse, J. Mueller, & M. Kirstein, Early Impacts of
the COVID–19 Pandemic: Findings From the 2020 Guttmacher
Survey of Reproductive Health Experiences, p. 4 (June 2020), https://
www.guttmacher.org /report /early-impacts-covid-19-pandemic-findings-
2020-guttmacher-survey-reproductive-health. Such delays were higher
among           Black,          Hispanic,          and         low-income
women.

    FDA v. AMERICAN COLLEGE OF OBSTETRICIANS AND
                     GYNECOLOGISTS
                   SOTOMAYOR, J., dissenting

weeks or later. 10 A woman seeking a medication abortion
may therefore be left with fewer than three weeks to find
an accessible clinic that will provide mifepristone, schedule
and receive the required counseling, 11 and make an ap-
pointment to collect the medication in person, all while try-
ing to determine the safest way to travel to the clinic and
perhaps wondering whether she will bring COVID–19 back
home with her.
   What rejoinder does the Government have to the possi-
bility that refusing to suspend the FDA’s in-person require-
ments for mifepristone during the COVID–19 pandemic
will cause some women to miss the 10-week window alto-
gether? No cause for concern, the Government assures this
Court, because even if the FDA’s in-person requirements
cause women to lose the opportunity for a medication abor-
tion, they can still seek out a surgical abortion. What a cal-
lous response.
   As the Government acknowledges, surgical abortions are
far more invasive than medication abortions. Medication
abortion involves taking two pills and the equivalent of an
early miscarriage. When a woman undergoes surgical abor-
tion, she requires local anesthesia and sometimes sedation,
her cervix is stretched with dilating rods, a tube is inserted
through her cervix into her uterus, and, depending on the
particular procedure, various medical tools are used to re-
move fetal tissue from her uterus. On top of this, surgical
abortions carry all the same (and likely greater) risks of ex-
posure to COVID–19 as do medication abortion’s in-person
requirements.
   The Government insists that requiring women to un-

——————
  10 See Branum & Ahrens, Trends in Timing of Pregnancy Awareness

Among US Women, 21 Maternal & Child Health J. 715, 719, 721–722
(2017).
  11 The required counseling can take place in person or via telemedicine,

although the patient must then sign a disclosure form in person.
                 Cite as: 592 U. S. ____ (2021)           9

                   SOTOMAYOR, J., dissenting

dergo a far more invasive abortion procedure does not im-
pose an undue burden on women’s right to abortion. In sup-
port, the Government points to Gonzales v. Carhart, 

(2007), in which this Court held that a ban on a
rare, second-trimester abortion procedure was not uncon-
stitutional, in part because “the vast majority” of second-
trimester abortions remained available.

This
Court has never held that the Government can ban one of
the most common and safest early abortion procedures
without running into constitutional problems. Indeed, in
Stenberg v. Carhart, 

(2000), this Court con-
cluded that a state ban on dilation and evacuation abortion,
“the most commonly used method for performing previabil-
ity second trimester abortions,” imposed an undue burden
on the right to choose abortion itself.

The
same reasoning extends to a regulation that, when applied
in the context of a deadly pandemic, prevents women from
accessing the most commonly used and safest method for
early abortions.
   The Government also argues that the pandemic has not
caused the FDA’s regulation to impose a meaningful burden
on women seeking medication abortions because in two
States that independently require in-person visits for med-
ication abortions (Indiana and Nebraska), there were more
abortions in 2020 than in 2019. This comparison, however,
provides little insight. For one, the Government does not
compare Indiana and Nebraska to States where the in-per-
son requirements for medication abortion have been sus-
pended, which may have seen even larger increases over
2019. Second, the Government provides data for just two
years, so it impossible to know whether the two States
simply saw an unusually low number of abortions in 2019.
Finally, the data does not distinguish between medication
and surgical abortions. For all anyone can tell, then, Indi-
ana and Nebraska may have seen a large increase in surgi-
cal abortions and a reduction in medication abortions. For
10   FDA v. AMERICAN COLLEGE OF OBSTETRICIANS AND
                    GYNECOLOGISTS
                  SOTOMAYOR, J., dissenting

the reasons discussed above, these procedures are not
equivalent. Reading the Government’s statistically insig-
nificant, cherry-picked data is no more informative than
reading tea leaves.
  Together, patients’ health vulnerabilities, public trans-
portation risks, susceptible older family members at home,
and clinic closures and reduced services pose substantial,
sometimes insurmountable, obstacles for women seeking
medication abortions during the COVID–19 pandemic. See
June Medical, 591 U. S., at ___–___ (plurality opinion) (slip
op., at 31–35);

___–___ (ROBERTS, C. J., concurring in
judgment) (slip op., at 11–16); Hellerstedt, 579 U. S., at ___–
___ (slip op., at 34–36). Under these conditions, the in-per-
son requirements for mifepristone impose an unjustifiable
and undue burden on a woman’s constitutional right to an
abortion.
                              B
   The District Court was therefore correct on the merits.
But even if it were not, the Government has not shown that
it will suffer any irreparable harm absent a stay of that
court’s injunction. The Government argues that all injunc-
tions against a government inherently cause irreparable
harm, especially for agencies charged with protecting pub-
lic health, and that courts should look no further. This
Court’s precedent does not support such a sweeping rule.
See, e.g., 

–1314 (considering
whether a state public health agency had shown irrepara-
ble harm from an injunction requiring the State to fund
medically necessary abortions).
   The Government points to no meaningful concrete harms.
It argues only that the in-person requirements mitigate
health risks from mifepristone “by allowing patients to re-
ceive in-person counseling about possible complications and
by avoiding potential delays associated with patients trying
                  Cite as: 592 U. S. ____ (2021)            11

                    SOTOMAYOR, J., dissenting

to obtain the drug from a pharmacy on their own.” Appli-
cation for Stay of Injunction 33. The former concern is un-
dermined by the fact that patients may receive physician
counseling remotely. The latter concern makes no sense:
The Government proposes to avoid delays by limiting
women’s options to obtain care quickly. Indeed, the evi-
dence before the District Court shows that the in-person re-
quirements are causing, not preventing, delays in obtaining
critical healthcare. Significantly, the FDA’s in-person re-
quirements for mifepristone have now been suspended for
six months, yet the Government has not identified a single
harm experienced by women who have obtained mifepris-
tone by mail or delivery.
                                 C
   The concurrence argues that courts should nonetheless
defer to the FDA’s decision not to lift mifepristone’s in-per-
son requirements during the pandemic. I agree that defer-
ence is due to reasoned decisions of public health officials
grappling with a deadly pandemic. See South Bay Pente-
costal Church v. Newsom, 590 U. S. ___, ___ (2020)
(ROBERTS, C. J., concurring in denial of application for in-
junctive relief) (slip op., at 2); see also Roman Catholic Dio-
cese of Brooklyn v. Cuomo, 592 U. S. ___, ___ (2020)
(SOTOMAYOR, J., dissenting) (slip op., at 2) (citing medical
expert declarations supporting challenged responses to the
current pandemic). But the record here is bereft of any
reasoning. The Government has not submitted a single dec-
laration from an FDA or HHS official explaining why the
Government believes women must continue to pick up mif-
epristone in person, even though it has exempted many
other drugs from such a requirement given the health risks
of COVID–19. There simply is no reasoned decision here to
which this Court can defer. Cf. Democratic National Com-
mittee v. Wisconsin State Legislature, 592 U. S. ___, ___
(2020) (KAGAN, J., dissenting in denial of application to va-
12   FDA v. AMERICAN COLLEGE OF OBSTETRICIANS AND
                    GYNECOLOGISTS
                  SOTOMAYOR, J., dissenting

cate stay) (slip op., at 7) (deference not due where the gov-
ernment “has not for a moment considered whether recent
COVID conditions demand changes”).
                         *     *     *
    This country’s laws have long singled out abortions for
more onerous treatment than other medical procedures
that carry similar or greater risks. See Greenhouse &
Siegel, Casey and the Clinic Closings: When “Protecting
Health” Obstructs Choice, 125 Yale L. J. 1428, 1430 (2016).
Like many of those laws, maintaining the FDA’s in-person
requirements for mifepristone during the pandemic not
only treats abortion exceptionally, it imposes an unneces-
sary, irrational, and unjustifiable undue burden on women
seeking to exercise their right to choose. One can only hope
that the Government will reconsider and exhibit greater
care and empathy for women seeking some measure of con-
trol over their health and reproductive lives in these unset-
tling times. See 

(Ginsburg, J.,
dissenting) (“[Women’s] ability to realize their full potential
. . . is intimately connected to their ability to control their
reproductive lives” (internal quotation marks omitted)).
For now, I respectfully dissent.